Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Challgren

MOHS-Micrographic Surgery Raleigh, NC Medical Doctor

NPI 1477508893 CMS profile 21807

4201 Lake Boone Trl, Suite 200, Raleigh, NC 27607

Open in the dashboard

General payments

$47,113

1,313 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Challgren of Raleigh, NC is reported in the CMS Open Payments database as having received $47,113 across 1,313 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,940 251
2024 General $7,391 254
2023 General $9,768 220
2022 General $4,486 233
2021 General $2,048 73
2020 General $3,493 116
2019 General $2,989 166

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Challgren
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Eric Challgren were reported at $16,940. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Eric Challgren MOHS-Micrographic Surgery median Middle half National median
2019 $2,989 $316 $106–$785 $163
2020 $3,493 $162 $68–$412 $114
2021 $2,048 $243 $87–$654 $132
2022 $4,486 $300 $102–$887 $149
2023 $9,768 $364 $125–$1,010 $160
2024 $7,391 $445 $142–$1,108 $164
2025 $16,940 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $15,883 136 payments
  2. E.R. Squibb & Sons, L.L.C. $6,100 67 payments
  3. AbbVie, Inc. $3,689 190 payments
  4. Sun Pharmaceutical Industries Inc. $2,642 119 payments
  5. Janssen Biotech, Inc. $1,999 99 payments
  6. Genentech USA, Inc. $1,766 23 payments
  7. Regeneron Healthcare Solutions, Inc. $1,657 59 payments
  8. Janssen Scientific Affairs, LLC $1,582 3 payments
  9. LEO Pharma Inc. $1,361 69 payments
  10. Incyte Corporation $1,350 64 payments
  11. Other $9,084 484 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $28,177 1,292 payments
  2. Consulting Fee $17,147 6 payments
  3. Education $935 12 payments
  4. Travel and Lodging $854 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $17,257 159 payments
  2. SOTYKTU $4,777 64 payments
  3. TREMFYA $3,409 89 payments
  4. RINVOQ $1,709 75 payments
  5. Xolair $1,634 15 payments
  6. ILUMYA $1,379 64 payments
  7. SKYRIZI $1,266 76 payments
  8. DUPIXENT Inflammation And Immunology $1,039 41 payments
  9. ADBRY $987 44 payments
  10. Otezla $871 36 payments
  11. Other $14,680 846 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,417

Median for Micrographic Dermatologic Surgery: 314

Drug cost

$429,474

Median for Micrographic Dermatologic Surgery: $3,836

Branded share of claims

15.6%

Median for Micrographic Dermatologic Surgery: 1.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 22 $159,583
Rinvoq Upadacitinib Brand 15 $112,076
Valchlor Mechlorethamine Hcl Brand 11 $65,632
Dupixent Pen Dupilumab Brand 12 $44,860
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 22 $16,228
Betamethasone Dipropionate Generic 98 $4,043
Tacrolimus Generic 27 $3,499
Fluorouracil Generic 28 $2,400
Azelaic Acid Generic 16 $2,359
Triamcinolone Acetonide Generic 135 $1,941

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 366 Part D prescribers listed as Micrographic Dermatologic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 104 billing codes

Paid by Medicare

$367,386

Of which drugs: $21,542

Medicare patients

889

Average age 76

Services billed

5,492

338 women, 551 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 41%
Ischemic heart disease 27%
Diabetes 21%
Atrial fibrillation 20%
Chronic kidney disease 19%
Cancer 19%
Heart failure 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 33 63 $41

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$1,514 12 —
SOTYKTU
$641 — —
TREMFYA
$437 — —
RINVOQ
$362 15 —
SKYRIZI
$304 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record